Lilly(LLY) ZACKS·2025-01-22 23:51Stock Performance - Eli Lilly closed at $753 98, marking a +1 57% move from the previous day, outpacing the S&P 500's daily gain of 0 61% [1] - Shares of the company had lost 6 7% over the past month, lagging the Medical sector's gain of 1 64% and the S&P 500's gain of 2 08% [1] Earnings and Revenue Projections - The company is predicted to post an EPS of $5 22, indicating a 109 64% growth compared to the equivalent quarter last year [2] - Revenue is expected to be $13 49 billion, showing a 44 23% escalation compared to the year-ago quarter [2] Analyst Estimates and Zacks Rank - Recent adjustments to analyst estimates reflect the latest near-term business trends, with upbeat changes indicating a favorable outlook on the company's business health and profitability [3] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has an impressive track record, with 1 stocks generating an average annual return of +25% since 1988 [4][5] - Eli Lilly currently possesses a Zacks Rank of 3 (Hold) [5] Valuation Metrics - Eli Lilly has a Forward P/E ratio of 31 3, indicating a premium compared to its industry's Forward P/E of 12 61 [6] - The company has a PEG ratio of 1 56, compared to the industry average of 1 32 [6] Industry Overview - The Large Cap Pharmaceuticals industry is part of the Medical sector and currently holds a Zacks Industry Rank of 207, positioning it in the bottom 18% of all 250+ industries [7] - The Zacks Industry Rank shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]